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Weappreciate the interest ofDrPatel and colleagues in our article
“Strategies to improve spinal cord ischemia in endovascular thoracic
aortic repair: Outcomes of a prospective cerebrospinal fluid drainage
protocol,” and are glad to hear that they agree with our findings that
although cerebrospinal fluid (CSF) drainage does help prevent spinal
cord ischemia after thoracic endovascular aneurysm repair (TEVAR),
it is not necessary in all patients and should be reserved for high-risk
patients who have had prior infrarenal aortic reconstructions and
planned extensive thoracic aortic and left subclavian artery coverage
without carotid–subclavian bypass.
We also appreciate Dr Patel and colleagues sharing their experi-
ence of complications of CSF drainage, and as stated in our article, we
agree that CSF drainage is not without its complications of subdural
and epidural hematoma, infection, and spinal headaches.
I think an epidural catheter/anesthesia is a good alternative to
general anesthesia for select patients undergoing TEVAR, but this
might have a limited role in patients who require coverage of the great
arch vessels at the proximal landing zones with extra-anatomic revas-
cularizations such as carotid–subclavian, with or without carotid–
carotid bypass, or complete arch debranching procedures.
We thank Dr Patel for his interest and for commenting on our
findings, and encourage him and his colleagues to report their
findings on the outcomes of emergency CSF drainage for patients
who develop spinal cord ischemia after TEVAR.
Manish Mehta, MD, MPH
The Institute for Vascular Health and Disease
Albany Medical Center
Albany, NY
doi:10.1016/j.jvs.2008.11.063
Regarding “Common femoral artery occlusive
disease: Contemporary results following
surgical endarterectomy”
We read with interest the article by Kang et al.1 We congrat-
ulate the authors on their impressive series and agree that the
operation of common femoral endarterectomy (CFE) offers an
excellent treatment formany patients and that this report may serve
as a standard for comparison with emerging endovascular thera-
pies. However, we disagree with their statement that the low
morbidity associated with CFE negates any presumed advantage of
endovascular therapy.
First, a procedure with an average duration of 3 hours, as
reported in this series, might be considered a considerable under-
taking under local anaesthetic. Many patients will find this uncom-
fortable, particularly with exposure to allow an arteriotomy well
proximal to the disease.
Second, although only one infected pseudoaneurysm is re-
ported in this series, many surgeons will be uncomfortable with
leaving a Dacron patch in the groin, notwithstanding the alterna-
tive of using a harvested vein patch would undoubtedly have
increased the operative time and wound complications.
Third, although open CFE will facilitate a concomitant fem-
oropopliteal bypass, no great advantage is offered for hybrid endo-
vascular procedures. Because CFE should be performed first to
preserve inflow during a distal endovascular procedure, the punc-
ture will necessarily be performed through the patch, offering the
potential for stenosis as it is sutured. An endovascular up-and-over
approach from the contralateral limb will offer the potential to
treat iliac, common femoral, and distal lesions with angioplasty
with or without stenting in sequence. This approach can be per-
formed in the angiography suite without need for facilitating both
open and endovascular procedures.
In our current practice, in addition to open CFE, we com-
monly perform CFA stenting with short, self-expanding stents forstenotic/occlusive disease. Decisions on the mode of therapy will
involve consideration of the anatomy of the disease, avoiding
compromise of profunda origin, the need for concomitant treat-
ments, and patient comorbidities. We are in no doubt that stenting
offers a successful and durable treatment, at least in the short- to
medium-term, and is a significantly less invasive procedure partic-
ularly suitable for elderly or unfit patients.
Michael Arthur Murphy, MD, FRCSI
Philip D. Colman, FRCAS, FRCS (Eng)
Department of Surgery
University of Newcastle
John Hunter Hospital
Newcastle, New South Wales, Australia
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Reply
Thank you for your interest in our article1 and below is our
response to your comments.
1. A variety of anesthetic choices are available for common femoral
artery (CFA) endarterectomy. Some 40% in our series were
performed with general anesthesia; if there are genuine reasons
to avoid it, spinal or local anesthesia can be used.
2. In response to the type of patch used for common femoral artery
endarterectomy (CFE), we do not routinely use vein patch for
CFE. In fact, the majority of CFEs included in this study were
performed using Dacron (59%), polytetrafluoroethylene (PTFE;
23%), or bovine pericardium (15%). There was only one deep
infection requiring re-exploration and removal of patch. We dis-
agree that surgeons are reluctant to use Dacron patches on the
CFA. In fact, it is rather standard practice in the United States.
3. In response to the comment that CFE offers no great advantage
in performing concomitant endovascular procedures, we dis-
agree. The sheath, placed through the center of the patch, can
easily be manipulated to treat an inflow and/or outflow disease
and the comment about creating a stenosis when suturing the
sheath puncture site is just plain silly.
4. Lastly, we would like to reiterate our stand that we believe most
lesions in the CFA are best treated via surgical endarterectomy.
While some patients may have limited, focal disease of the CFA
allowing for a short stent placement to treat their lesions,2 most
patients with disease in the CFA have extensive, bulky, calcified
plaques that are best treated with open surgical approach.While
the authors are “in no doubt” about the value of CFA stenting,
there is no evidence base to support their conviction.
Jeanwan Kang, MD
Richard Cambria, MD
Massachusetts General Hospital
Boston, Mass
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